NCT04742959View on ClinicalTrials.gov

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

March 14, 2021

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions
Advanced Solid TumorCholangiocarcinomaHER2-negative Breast CancerTriple Negative Breast CancerBladder CancerSmall-cell Lung CancerProstate CancerThyroid CancerSarcomaGastric CancerGallbladder Cancer
Interventions
DRUG

TT-00420

TT-00420 tablet will be administered orally once daily per protocol defined schedule.

COMBINATION_PRODUCT

Nab-Paclitaxel

Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle

Trial Locations (6)

44718

Gabrail Cancer Center Research, Canton

60637

The University of Chicago, Chicago

75390

UT Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

08901

Rutgers Cancer Institute, New Brunswick

All Listed Sponsors
lead

TransThera Sciences (Nanjing), Inc.

INDUSTRY

NCT04742959 - Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter